Further Amendment to Duties Addressing the Synthetic Opioid Supply Chain in the People's Republic of China
Executive Order
•
March 07, 2025
•
Document 2025-03775
Summary
President Donald Trump signed Executive Order 14228, increasing tariffs from 10% to 20% on Chinese products in response to China's inadequate efforts to curb the flow of synthetic opioids, like fentanyl, into the U.S. This action aims to pressure China into taking more effective measures against the opioid crisis, which poses a significant threat to U.S. national security and economy. The order could escalate trade tensions between the two countries and has potential legal implications under international trade laws.
Full Text
[Federal Register Volume 90, Number 44 (Friday, March 7, 2025)]
[Presidential Documents]
[Pages 11463-11464]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2025-03775]
Presidential Documents
Federal Register / Vol. 90, No. 44 / Friday, March 7, 2025 /
Presidential Documents
___________________________________________________________________
Title 3--
The President
[[Page 11463]]
Executive Order 14228 of March 3, 2025
Further Amendment to Duties Addressing the
Synthetic Opioid Supply Chain in the People's Republic
of China
By the authority vested in me as President by the
Constitution and the laws of the United States of
America, including the International Emergency Economic
Powers Act (50 U.S.C. 1701 et seq.) (IEEPA), the
National Emergencies Act (50 U.S.C. 1601 et seq.),
section 604 of the Trade Act of 1974, as amended (19
U.S.C. 2483), and section 301 of title 3, United States
Code, I hereby determine and order:
Section 1. Background. With Executive Order 14195 of
February 1, 2025 (Imposing Duties to Address the
Synthetic Opioid Supply Chain in the People's Republic
of China), I determined that the failure of the
Government of the People's Republic of China (PRC) to
act to blunt the sustained influx of synthetic opioids,
including fentanyl, flowing from the PRC to the United
States constituted an unusual and extraordinary threat,
which has its source in substantial part outside the
United States, to the national security, foreign
policy, and economy of the United States. To address
that threat, I invoked my authority under section
1702(a)(1)(B) of IEEPA to impose ad valorem tariffs on
articles that are products of the PRC, as defined by
the Federal Register notice described in section 2(d)
of Executive Order 14195, as amended by Executive Order
14200 of February 5, 2025 (Amendment to Duties
Addressing the Synthetic Opioid Supply Chain in the
People's Republic of China).
Pursuant to section 3 of Executive Order 14195, I have
determined that the PRC has not taken adequate steps to
alleviate the illicit drug crisis through cooperative
enforcement actions, and that the crisis described in
Executive Order 14195 has not abated.
Sec. 2. Amendment. In recognition of the fact that the
PRC has not taken adequate steps to alleviate the
illicit drug crisis, section 2(a) of Executive Order
14195 is hereby amended by striking the words ``10
percent'' and inserting in lieu thereof the words ``20
percent''.
Sec. 3. General Provisions. (a) Nothing in this order
shall be construed to impair or otherwise affect:
(i) the authority granted by law to an executive department, agency, or the
head thereof; or
(ii) the functions of the Director of the Office of Management and Budget
relating to budgetary, administrative, or legislative proposals.
(b) This order shall be implemented consistent with
applicable law and subject to the availability of
appropriations.
[[Page 11464]]
(c) This order is not intended to, and does not,
create any right or benefit, substantive or procedural,
enforceable at law or in equity by any party against
the United States, its departments, agencies, or
entities, its officers, employees, or agents, or any
other person.
(Presidential Sig.)
THE WHITE HOUSE,
March 3, 2025.
[FR Doc. 2025-03775
Filed 3-6-25; 8:45 am]
Billing code 3395-F4-P